NCT05324332View on ClinicalTrials.gov

68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients

NARecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 15, 2022

Primary Completion Date

January 1, 2025

Study Completion Date

December 31, 2025

Conditions
Prostate Cancer
Interventions
DRUG

68Ga-P16-093

Intravenous injection of 68Ga-P16-093 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.

DRUG

68Ga-PSMA-11

Intravenous injection of 68Ga-PSMA-11 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-PSMA-11 will be used to image lesions of prostate cancer by PET/CT.

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER